Oculis initiated with an Overweight at JPMorgan

JPMorgan analyst Tessa Romero initiated coverage of Oculis (OCS) with an Overweight rating and $38 price target The firm says Oculis has a diversified ophthalmology pipeline with “multiple shots on goal” in eye indications with high unmet need. The company’s most advanced asset OCS-01 has shown “supportive” efficacy and safety in diabetic macular edema with its non-invasive and patient-friendly eye drop approach, the analyst tells investors in a research note. JPMorgan sees the shares as well positioned for upside as Oculis generates additional data.